Osteosarcoma

Aspirin is more interesting in osteosarcoma than most readers expect.

This is still a preclinical page. There is no adjuvant Phase 3 aspirin trial in osteosarcoma. But the field has two things that matter. First, it has a landmark 2015 Clinical Cancer Research paper showing direct anti-tumour and anti-metastatic activity. Second, it now has a newer mechanistic layer through PDE4D, which may help explain why aspirin is relevant in this disease beyond its broader anti-inflammatory profile. Read the 2015 paper

The clinical importance is also unusually clear. The two hardest osteosarcoma problems are lung metastasis and cisplatin resistance. Those are exactly the areas where aspirin has shown the most direct mechanistic relevance. Read the 2026 paper

Overview

Osteosarcoma is the most common primary malignant bone tumour.

It affects mainly children, adolescents, and young adults. Survival remains much worse once metastatic disease is present, especially when the lungs are involved.

Aspirin matters here mainly through NF-κB suppression. That pathway helps drive osteosarcoma cell survival, migration, invasion, and treatment resistance. Aspirin has repeatedly been shown to suppress this pathway in osteosarcoma models. Read the 2015 paper

The newer PDE4D finding adds a second angle. It suggests aspirin may also dismantle a more specific osteosarcoma growth program linked to poorer outcomes. Read the 2026 paper

Key findings

The landmark 2015 AACR study

This remains the core osteosarcoma aspirin paper.

In this work, aspirin showed direct anti-tumour effects across osteosarcoma models and also affected the parts of the disease that matter most clinically. Read the paper

Key findings included:

• aspirin reduced osteosarcoma cell viability in a dose-dependent and time-dependent way

• aspirin sensitised osteosarcoma cells to cisplatin in both cell-line and animal models

• aspirin reduced migration and invasion in vitro

• aspirin markedly reduced lung metastases in osteosarcoma xenograft models

• the mechanism was linked to NF-κB pathway suppression

The lung-metastasis result is the most important part of the paper.

In osteosarcoma, lung spread is the dominant metastatic pattern and a major reason survival falls so sharply in advanced disease. A preclinical finding that directly reduces pulmonary metastasis is therefore more meaningful here than a generic anti-proliferative result.

The 2026 PDE4D finding

The 2026 paper adds something genuinely new.

It identified PDE4D as a highly expressed oncogenic driver in osteosarcoma and linked higher expression to worse patient outcomes. Aspirin was shown to suppress PDE4D through the NF-κB / p65 → PDE4D promoter axis. Read the paper

That matters for three reasons:

• it gives osteosarcoma a more specific aspirin-sensitive target

• it helps explain anti-proliferative effects that are not fully captured by broad NF-κB language alone

• it raises the possibility that PDE4D-high tumours could become a future biomarker-defined subgroup

This is still early.

But it is the kind of finding that can shift a page from “interesting old mechanism” to “active evolving research area.”

Earlier cell-line evidence

A 2011 MG-63 cell-line study also reported direct anti-proliferative effects of aspirin in osteosarcoma cells. Read the paper

That older work matters less than the 2015 and 2026 studies, but it helps show continuity. The aspirin signal in osteosarcoma was not a one-off observation.

Mechanistic relevance

NF-κB suppression

This is the central osteosarcoma mechanism.

NF-κB is persistently active in many osteosarcoma models and supports:

• tumour-cell survival

• resistance to apoptosis

• migration and invasion

• angiogenesis-related signalling

• chemotherapy resistance, including cisplatin resistance

Aspirin suppresses this pathway and lowers downstream invasion and metastasis signals. Read the 2015 paper

Cisplatin sensitisation

This is one of the most clinically relevant osteosarcoma findings.

Cisplatin remains one of the core drugs in osteosarcoma treatment. Resistance to it is a major problem in relapsed or refractory disease.

The 2015 study showed that aspirin and cisplatin worked synergistically, not just additively, in osteosarcoma models. Read the 2015 paper

That does not prove clinical benefit yet.

But it does make osteosarcoma one of the clearer aspirin pages for chemotherapy-sensitisation logic.

Lung metastasis and platelet biology

The 2015 osteosarcoma paper showed a direct reduction in lung metastases.

A second mechanistic layer comes from broader platelet biology. Circulating tumour cells can use platelet-derived TXA2 and platelet cloaking to evade immune killing during metastatic spread. That systemic mechanism was clarified in the 2025 Nature work on the TXA2 → ARHGEF1 → CD8-positive T-cell suppression axis. Read the Cambridge summary

There is no osteosarcoma-specific randomised trial proving this pathway explains the metastasis result.

But the biology is coherent. In a disease where lung dissemination is the main metastatic threat, aspirin's platelet and TXA2 effects are highly relevant.

For the broader mechanism, see Aspirin and Thromboxane A2 (TXA2).

PDE4D and cAMP signalling

PDE4D breaks down intracellular cAMP.

Because cAMP can restrain proliferation in some tumour contexts, higher PDE4D activity can help create a more growth-permissive environment. By downregulating PDE4D, aspirin may shift intracellular signalling in an anti-proliferative direction in osteosarcoma cells. Read the 2026 paper

That makes PDE4D one of the most interesting new osteosarcoma biomarkers to watch.

VTE prophylaxis context

Aspirin is also relevant in osteosarcoma for a different reason.

Orthopaedic-oncology patients have meaningful venous thromboembolism risk, especially around large limb-sparing procedures, reconstructions, and reduced mobility. A current trial is comparing low molecular weight heparin with aspirin for postoperative VTE prophylaxis in orthopaedic-oncology patients. Read the trial record

This is not an anti-tumour aspirin trial.

But it still matters because it shows aspirin is already entering formal clinical infrastructure in the surgical bone-oncology setting.

Clinical positioning

Honest evidence assessment

This page is still entirely preclinical on the anti-tumour side.

That limit matters. There is no human trial showing that aspirin improves metastasis-free survival, overall survival, or chemotherapy response in osteosarcoma patients.

Even so, the page is stronger than many purely mechanistic pages because the preclinical findings are tightly aligned with the disease's main clinical failure points:

• lung metastasis

• cisplatin resistance

The newer PDE4D work also adds a plausible future biomarker story rather than just repeating generic anti-inflammatory biology.

Practical interpretation

This is a page worth following, especially for families dealing with relapsed, metastatic, or high-risk osteosarcoma.

The most useful questions are:

1. Is the key issue lung metastasis, cisplatin resistance, or both?

2. Has anyone discussed the tumour's NF-κB or possibly future PDE4D relevance?

3. Is aspirin being discussed in a surgical VTE-prevention context, which is a different question from direct anti-tumour use?

4. In younger patients, has the team weighed age-specific aspirin safety, bleeding risk, and perioperative timing carefully?

That last point matters.

Because osteosarcoma often affects children and adolescents, aspirin should not be treated as a casual add-on. Any discussion belongs with the paediatric oncology or orthopaedic oncology team.

References

• Tian et al., Clinical Cancer Research 2015 — aspirin suppresses osteosarcoma growth and metastasis through NF-κB-linked mechanisms. Read the paper

• AACR journal version of the 2015 study — includes the lung-metastasis findings. Read the journal article

• 2026 study — aspirin downregulates PDE4D via the NF-κB / p65 axis in osteosarcoma. Read the paper

• 2011 MG-63 cell-line study — early anti-proliferative evidence for aspirin in osteosarcoma. Read the paper

• Yang et al., Nature 2025 — platelet TXA2, immune escape, and metastatic spread. Read the Cambridge summary

• Orthopaedic-oncology VTE trial — aspirin versus low molecular weight heparin after surgery. Read the trial record

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form